<p>The Hyderabad-based vaccine manufacturer Bharat Biotech on Thursday said that the recent study on Covaxin provides 'evidence for effectiveness' of India's first indigenous vaccine against Covid-19.</p>.<p>Reacting to a real-world assessment, which said that Covaxin is 50 per cent effective against symptomatic Covid-19, Bharat Biotech said, "These results provide evidence for effectiveness for Covaxin in real life settings."</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/business/business-news/developing-covaxin-was-an-enormous-challenge-bharat-biotech-1052288.html" target="_blank">Developing Covaxin was an enormous challenge: Bharat Biotech</a></strong></p>.<p>The vaccine manufacturer said, "Bharat Biotech commends the investigators from AIIMS on the BBV152 study published in Lancet Infectious Diseases."</p>.<p>The firm further said, "An effectiveness result of 50 per cent achieved during the peak Covid-19 Delta variant wave in India, in a high-risk study population of physicians and healthcare workers, in a health-related environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin."</p>.<p>In a study published in the journal <em><strong><a href="http://Covaxin shows 50% effectiveness against Covid Delta variant: Lancet study" target="_blank">The Lancet</a></strong>,</em> earlier this month, Bharat Biotech demonstrated Covaxin to be 77.8 per cent effective against Covid-19, and 65.2 per cent against Delta variant.</p>.<p>However, in the latest study researchers at AIIMS acknowledged that the vaccine effectiveness is lower than the efficacy reported by a recently published phase-III randomised control study of BBV152.</p>.<p>Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2 infection, and 1,097 tested negative. The adjusted vaccine effectiveness against symptomatic Covid-19 after two doses of BBV152 with the second dose administered 14 or more days before undergoing RT-PCR testing was 50 per cent.</p>.<p>On the Delta variant, Bharat Biotech noted, "These results compare well with the 65.2 per cent efficacy obtained during the controlled Phase 3 clinical trials of Covaxin conducted among the general population."</p>.<p>Covaxin shot developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV), in July announced the final results of its Phase-III clinical trials.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>
<p>The Hyderabad-based vaccine manufacturer Bharat Biotech on Thursday said that the recent study on Covaxin provides 'evidence for effectiveness' of India's first indigenous vaccine against Covid-19.</p>.<p>Reacting to a real-world assessment, which said that Covaxin is 50 per cent effective against symptomatic Covid-19, Bharat Biotech said, "These results provide evidence for effectiveness for Covaxin in real life settings."</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/business/business-news/developing-covaxin-was-an-enormous-challenge-bharat-biotech-1052288.html" target="_blank">Developing Covaxin was an enormous challenge: Bharat Biotech</a></strong></p>.<p>The vaccine manufacturer said, "Bharat Biotech commends the investigators from AIIMS on the BBV152 study published in Lancet Infectious Diseases."</p>.<p>The firm further said, "An effectiveness result of 50 per cent achieved during the peak Covid-19 Delta variant wave in India, in a high-risk study population of physicians and healthcare workers, in a health-related environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin."</p>.<p>In a study published in the journal <em><strong><a href="http://Covaxin shows 50% effectiveness against Covid Delta variant: Lancet study" target="_blank">The Lancet</a></strong>,</em> earlier this month, Bharat Biotech demonstrated Covaxin to be 77.8 per cent effective against Covid-19, and 65.2 per cent against Delta variant.</p>.<p>However, in the latest study researchers at AIIMS acknowledged that the vaccine effectiveness is lower than the efficacy reported by a recently published phase-III randomised control study of BBV152.</p>.<p>Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2 infection, and 1,097 tested negative. The adjusted vaccine effectiveness against symptomatic Covid-19 after two doses of BBV152 with the second dose administered 14 or more days before undergoing RT-PCR testing was 50 per cent.</p>.<p>On the Delta variant, Bharat Biotech noted, "These results compare well with the 65.2 per cent efficacy obtained during the controlled Phase 3 clinical trials of Covaxin conducted among the general population."</p>.<p>Covaxin shot developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV), in July announced the final results of its Phase-III clinical trials.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>